文献速递骨质疏松与代谢性骨病

生物类似药地舒单抗治疗绝经后骨质疏松的成本效果:基线骨折风险与药品价格的影响

The cost-effectiveness of biosimilar denosumab in postmenopausal osteoporosis: implications of baseline fracture risk and drug price.
PubMed 文献 · Osteoporos Int · 2026-07-31

本研究采用经验证的马尔可夫队列模型,评估美国绝经后骨质疏松女性中使用生物类似药地舒单抗相较于双膦酸盐类药物及不干预的成本效果,并按T值和既往椎体骨折将患者分为4个风险等级。结果显示,随着骨折风险升高,生物类似药地舒单抗的成本效果改善;在充分降价时,其在不同基线骨折风险水平下均为优势策略。

要点

  • 生物类似药地舒单抗在充分降价时,跨不同基线骨折风险水平均为优势策略。
  • 风险等级1至4(风险递增)对应的优势价格区间分别为120–180、376–451、376–481和857–1188美元。
  • 降价75%(即376美元)时,生物类似药地舒单抗在风险等级2、3、4中相较于所有对照均具优势。

核心结论

  • 在充分降价的前提下,生物类似药地舒单抗在不同基线骨折风险水平下均为优势策略,即更有效且成本更低。
  • 鉴于其相较于双膦酸盐的优效性和良好安全性,以及预期的价格下降,生物类似药地舒单抗可能被视为美国高骨折风险绝经后骨质疏松女性的一线治疗选择。

研究设计与样本

  • 研究采用经验证的马尔可夫队列模型,评估生物类似药地舒单抗对比阿仑膦酸钠、利塞膦酸钠、伊班膦酸钠、唑来膦酸及不干预的成本效果。
  • 患者根据T值和既往椎体骨折被分为4个风险等级,分析探讨了基线骨折风险变化和生物类似药地舒单抗定价的影响。

主要发现

  • 生物类似药地舒单抗的成本效果随骨折风险增加而改善(风险等级1至4代表风险递增)。
  • 生物类似药地舒单抗在风险等级1、2、3、4中成为优势策略的价格区间分别为120–180、376–451、376–481和857–1188美元。
  • 在降价75%(即376美元)时,生物类似药地舒单抗在风险等级2、3、4中相较于所有对照均为优势策略。

临床怎么用

  • 对于美国高骨折风险的绝经后骨质疏松女性,在生物类似药地舒单抗价格充分降低时,可考虑将其作为一线治疗以在更低总成本下改善健康。
  • 临床决策可结合患者基线骨折风险等级和当地生物类似药地舒单抗实际价格,参考研究中各风险等级对应的优势价格区间进行评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Biosimilar denosumab is a dominant treatment strategy (i.e., more effective and less costly) across varying levels of baseline fracture risk with sufficient price reductions. Given its superior efficacy and safety, it may be considered a first-line therapy for the treatment of women with postmenopausal osteoporosis at high risk of fracture in the United States (US). Large-scale adoption of biosimilar denosumab as a first-line therapy in this population is anticipated to lead to health improvements at a lower overall cost. PURPOSE: Postmenopausal osteoporosis (PMO) remains undertreated in the US. According to clinical practice guidelines, bisphosphonates and denosumab are recommended therapies for women at high risk of fracture, but bisphosphonates have been preferred due to lower cost. The introduction of biosimilar denosumab may reduce prices and improve access. This study evaluates the cost-effectiveness of biosimilar denosumab compared to bisphosphonates and no intervention in women with PMO in the US across different baseline fracture risks and biosimilar denosumab pricing scenarios. METHODS: A validated Markov cohort model estimated cost-effectiveness of biosimilar denosumab versus alendronate, risedronate, ibandronate, zoledronic acid, and no intervention. Patients were stratified into four risk categories based on T-score and prior vertebral fracture. The analyses explored the impact of changes in baseline fracture risk and biosimilar denosumab pricing. RESULTS: The cost-effectiveness of biosimilar denosumab improved with increasing fracture risk (categories 1-4 represent increasing risk). Biosimilar denosumab was dominant (i.e., more effective and less costly) when priced at $120-$180, $376-$451, $376-$481, and $857-$1188 for risk categories 1, 2, 3, and 4, respectively. At a 75% price reduction (i.e., $376), biosimilar denosumab was dominant versus all comparators for risk categories 2, 3, and 4. CONCLUSION: With sufficient price reductions, biosimilar denosumab is a dominant strategy across varying levels of baseline fracture risk. Biosimilar denosumab's superior efficacy and favorable safety profile compared to bisphosphonates, along with anticipated price declines, support its potential as a first-line therapy for women with PMO at high-risk of fracture in the US.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Li E, Mirzayeh Fashami F, Kane S, et al. The cost-effectiveness of biosimilar denosumab in postmenopausal osteoporosis: implications of baseline fracture risk and drug price. Osteoporos Int. 2026. PMID: 42533098. doi:10.1007/s00198-026-08153-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。